title: [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
authors.affiliation: Servicio de Reumatología, Hospital de Sant Rafael, Barcelona, España. Electronic address: dgrados23@hotmail.com.
authors.forename: Dolors
authors.initials: D
authors.lastname: Grados
authors.affiliation: Servicio de Reumatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
authors.forename: Melania
authors.initials: M
authors.lastname: Martínez-Morillo
authors.affiliation: Servicio de Reumatología, Hospital Germans Trias i Pujol, Badalona, Barcelona, España.
authors.forename: Susana
authors.initials: S
authors.lastname: Holgado
authors.affiliation: Servicio de Reumatología, Hospital de Sant Rafael, Barcelona, España.
authors.forename: Alba
authors.initials: A
authors.lastname: Erra
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid